Associate Professor Dong-Xu Liu

profile image

Associate Professor

Phone: 09 921 9999 ext 6722

Email: dong-xu.liu@aut.ac.nz

Physical Address:
WS562,
WS Building,
34 St Paul Street,
Auckland 1010,
New Zealand

Postal Address:

School of Science,
Auckland University of Technology,
C-42, Private Bag 92006,
Auckland 1142,
New Zealand



ORCID:
ORCID logo  https://orcid.org/0000-0002-5949-7889

Links to relevant web pages:

TVNZ 1NewsNow (1 Mar 2019): Scientists closer to bringing tool to guide clinical decision making for treating breast cancer to the market

Survivor and Breast Cancer Cure trustee Fay Sowerby spoke to TVNZ1’s Breakfast about findings published in the British Journal of Cancer. 

Survivor and Breast Cancer Cure trustee Fay Sowerby spoke to TVNZ1’s Breakfast about Associate Professor Dong-Xu Liu's findings published in the British Journal of Cancer. Source: Breakfast.

NZ Herald (28 Feb 2019): NZ study helps doctors predict best treatment for breast cancer patients

AUT University Associate Professor Dong-Xu Liu's research could help predict the best treatment for breast cancer patients. 

AUT University Associate Professor Dong-Xu Liu's research could help predict the best treatment for breast cancer patients.

The 2016 Merck KGaA Grant for Oncology Innovation (GOI) Award: https://www.grantforoncologyinnovation.org/en/goi2016/winners.html

AUT University Associate Professor Dong-Xu Liu (left) was one of the only three 2016 GOI award winners 

AUT University Associate Professor Dong-Xu Liu (left) was one of the only three 2016 GOI award winners.


Associate Investigator, the MedTech CoRE: https://www.cmdt.org.nz/staff-member/aprof-dong-xu-liu

Qualifications:

  • 1983-1987, BSc in genetics, China Agricultural University, Beijing
  • 1989-1992, MSc in genetics, Chinese Academy of Sciences: Chengdu Institute of Biology, Chengdu
  • 1997-2000, PhD in medicine, National University of Singapore, Singapore 

Memberships and Affiliations:

Membership of Professional Organizations

  • Founding President of the NZ Association of Breast Cancer Research (2017- ).
  • Chair of the Organising Committee of the Inaugural NZ Breast Cancer Symposium (NZBCS-2017), 12-14 Nov 2017, Auckland, New Zealand.
  • The Editorial Board of Scientific Reports (UK) (2017-).
  • The Editorial Board of Journal of Cancer Metastasis and Treatment (2017-2018).
  • The Editorial Board of Tumor and Microenvironment (2017-).
  • The Editorial Board of Oncology Reports (2012-2014).
  • The American Association for Cancer Research, USA.
  • The Endocrine Society, USA.
  • New Zealand Society for Oncology, New Zealand.
  • The New Zealand Chinese Scientists Association.
  • The Auckland Cancer Research Network.

Reviewer for Journals including Cancer Research (AACR Journals); Clinical Cancer Research (AACR Journals); Molecular Cancer Therapeutics (AACR Journals); Oncogene; Scientific Reports; Endocrinology; New Zealand Medical Journal; Trends in Cancer, and so on.

Biography:

In 1983 Dr Liu went to the China Agricultural University, one of the national top 10 key universities in China and graduated in 1987 with a BSc in plant genetics and breeding. After worked at the Mianyang Institute of Agricultural Sciences from 1987 to 1989, he studied at the Chinese Academy of Sciences: Chengdu Institute of Biology for three years and earned his MSc in genetics in 1992. He worked in the Medical Laboratory of Molecular Biology at then West China University of Medical Sciences, now part of the Sichuan University for two years, carrying out medical research on genetic diseases (beta-thalassemia) and multidrug resistance of tumours. From July 1994 to October 1995, he was a visiting scholar at the Royal Marsden Hospital: Institute of Cancer Research, London, United Kingdom, participating in a programme to identify genes differentially expressed between the normal and malignant breast tissues. He successfully identified five novel PI 3-kinases which were not found by other competitors in the area at that time. He later studied at the University of Westminster with the support of an Overseas Research Student Award from the British Government. He was awarded a three year PhD scholarship by the National University of Singapore in 1997 to read for a PhD in medicine, which was conferred in 2001. Dr Liu held a post-doctoral fellowship position at the Institute of Molecular and Cell Biology (IMCB), A*Star, Singapore for 4 years from 2000 to 2004 before he took a more senior position at the Liggins Institute, University of Auckland, where he spent more than 12 years doing breast cancer research. In August 2016 he joined in the Auckland University of Technology as an Associate Professor.

Teaching Areas:

  • Biomedical Science and Technology (BIOL742)
  • Specialist Readings in Applied Science (SCIE803)
  • Cancer Biology (under development)
  • Introduction to Cancer Biology (under development)

Research Areas:

His research interests include breast cancer biology, growth hormone signalling, oncogenes and molecular therapeutics.

Research Summary:

Dr Liu's laboratory currently focuses on the identification of diagnostic and prognostic biomarkers for breast cancer, and the development of therapeutic agents that target specific growth factors or molecules involved in cancer growth and progression. His work has attracted much attention in the area of anticancer drug development. He has been invited to give plenary talks at national and international conferences and present his work at many research institutes and universities. He has active collaboration with researchers in other universities and organizations around the world. Through collaboration with Prof. Ian Ellis and Dr Andrew Green, world well-known breast cancer pathologists at the Nottingham City Hospital, he has access to the Breast Cancer Now Tissue Bank of United Kingdom - the world’s largest breast cancer tissue bank with a collection of more than 2,000 breast cancer tissues, which facilitates the translation of pre-clinical laboratory advances into clinical practice. By analysing the expression of SHON protein (one of the oncoproteins he identified and named) in a cohort of 1,650 breast cancer tissue samples, he demonstrated that SHON was a potential biomarker for predicting patient response to anti-estrogen therapy. This finding itself was very exciting and had a very significant clinical significance because anti-estrogen therapy is the mainstay of treatments for three quarters of breast cancer patients whose tumour are ER positive, but up to 50% of these patients do not response due to drug resistance. SHON thus has the potential utility in selecting the right patients for such treatments, avoiding giving ineffective treatments to non-responders. This work was published in the prestigious oncology journal Cancer Research (DOI: http://dx.doi.org/10.1158/0008-5472.CAN-13-0982), which is the most highly cited cancer journal in the world and published by the American Association for Cancer Research (AACR). His work was highly regarded by both the editors and the reviewers, being commented as “an outstanding manuscript” and “the authors should be commended on producing this manuscript”. His lab is now working to understand how SHON drives the progression of breast cancer and to commercialise the SHON biomarker in anti-estrogen therapy.

In collaboration with Prof. Steve Chan at the Nottingham City Hospital, a mega analysis of more than 10,000 clinical breast cancer samples has identified that a gene, called SPAG5 (sperm associated antigen 5) and also known as astrin, is a novel chemotherapy biomarker and a potential therapeutic target: 1) amplification/gain of the SPAG5 locus at Ch17q11·2 was found in about 20% of all breast cancers; 2) the SPAG5-gene-copy number aberrations and its transcript and protein were associated with poor clinical outcome and adverse clinicopathological features, including TP53-mutation, PAM50-LumB, and PAM50-HER2; and 3) both high expression of SPAG5 mRNA transcript and protein are independent predictors for response to chemotherapy. These findings have been published in the Lancet Oncology journal (DOI: http://dx.doi.org/10.1016/S1470-2045(16)00174-1), together with a commentary report titled "SPAG5: the ultimate marker of proliferation in early breast cancer?" by François Bertucci, Patrice Viens, and Daniel Birnbaum (DOI: http://dx.doi.org/10.1016/S1470-2045(16)30092-4). The Lancet Oncology journal has an impact factor of 36.418 in 2017 and ranks third out of 202 oncology journals worldwide, is the leading clinical research journal in oncology, and is in the top 0.5% of all scientific journals, of any discipline, globally.

In the past 18 years he has taken part in quite a number of commercial projects involving the identification of therapeutic targets for cancer. As an inventor, he holds 14 international patents for potential therapeutic targets for cancer. He was one of the two founding scientists of Saratan Therapeutics Ltd, a biotech entity focused on the development of therapeutics to novel cancer target molecules. He has recently signed a contract with a Singapore biocompany to look at the possibility to use SHON as a blood biomarker for early diagnosis of breast cancer.

As a principal investigator and research scientist, Dr Liu has proven experience and expertise in most areas of molecular and cellular oncology and is familiar with many techniques. He has supervised/co-supervised 12 BSc (honours), 6 MSc and 16 PhD students. Although translational/commercial research limited his academic outputs, he has 55 publications in prestigious journals such as Cancer Research (2017 impact factor 9.130), Lancet Oncology (36.418), Oncogene (6.854), Cell Death & Differentiation (8.000), Molecular Cancer Research (4.597), Endocrinology (3.961), Molecular Cancer Therapeutics (5.365), Neoplasia (4.994), The Journal of Biological Chemistry (4.010), Breast Cancer Research (6.142), International Journal of  Cancer (7.360), Cancer Letter (6.491), and Scientific Reports-UK (4.122).

Current Research Projects:

Research Funding

Dr Liu’s research has been funded by the New Zealand Government and charitable trusts including the Margaret Morley Medical Trust, the Maurice & Phyllis Paykel Trust, the Kelliher Charitable Trust. He has won several prestigious research grants from the New Zealand Breast Cancer Foundation, the Breast Cancer Cure Trust, the Auckland Medical Research Foundation, the Health Research Council (HRC) of New Zealand and the Lottery Health Research of New Zealand. In 2016, he won one of the three winners of the Merck KGaA Grant for Oncology Innovation (GOI), which was announced during the 2016 ESMO Congress in Copenhagen, Denmark (http://www.grantforoncologyinnovation.org). The three GOI winners were selected from 405 applications from 49 countries across the globe and Dr Liu was the only winner who is from outside of the European region since the establishment of the Grant.

Current Research Projects

  • Novel Immunotherapies for breast cancer.
  • How does SHON expression in tumours determine the efficacy of endocrine therapy in breast cancer?
  • Therapeutic potential of monoclonal antibodies targeting the novel oncoprotein SHON for breast cancer treatment.
  • Identification of the receptors and binding partners for SHON, a novel secreted oncoprotein.
  • Artemin as a diagnostic and prognostic biomarker for breast cancer.
  • Targetability study of SPAG5 in breast cancer treatment.

Scholarships

AUT offers a variety of scholarships to both domestic and international students who want to do a postgraduate degree at AUT. More information on available scholarships can be found here: Scholarships and awards at AUT.

AUT-China Scholarship Council (CSC) scholarships: Top students from China are eligible to apply for these AUT-CSC scholarships. Students who receive a scholarship will be provided with a living allowance, return airfare to New Zealand, student visa fees, and the cost of health insurance for international students.

Prospective students are encouraged to discuss with Dr Liu about their research interests in breast cancer research before applying for any scholarships.

Publications:

Books:
  • Li Z and Liu D. Research Methods and Techniques in Plant Cytogenetics. Chengdu: Sichuan Sciences and Technologies Publishing House, 1992.

Full articles (selected):

    • Abdel-Fatah TMA, Broom RJ, Lu J, Moseley PM, Huang B, Li L, Liu S, Chen L, Ma RZ, Cao W, Wang X, Li Y, Perry JK, Aleskandarany M, Nolan CC, Rakha EA, Lobie PE, Chan SYT, Ellis IO, Hwang LA, Lane DP, Green AR, Liu DX. SHON expression predicts response and relapse risk of breast cancer patients after anthracycline-based combination chemotherapy or tamoxifen treatment. British Journal of Cancer 2019. (in press) (2017 IF = 5.922)
    • Liu B, Du R, Zhou L, Xu J, Chen S, Chen J, Yang X, Liu DX, Shao ZM, Zhang L, Yu Z, Xie N, Guan JL, Liu S. miR-200c/141 Regulates Breast Cancer Stem Cell Heterogeneity via Targeting HIPK1/β-Catenin Axis. Theranostics 2018; 8(21):5801-5813. doi:10.7150/thno.29380. (2017 IF = 8.537)
    • Dantzic, D.; Noel, P.; Merien, F.; Liu, D.-X.; Lu, J.; Han, H.; McKeage, M.J.; Li, Y. The Effects of Synthetically Modified Natural Compounds on ABC Transporters. Pharmaceutics 2018 Aug 9;10(3). pii: E127. doi: 10.3390/pharmaceutics10030127. (2017 IF = 3.746)
    • Alfarsi L, Johnston S, Liu DX, Rakha E, Green A. Current issues with luminal subtype classification in terms of prediction of benefit from endocrine therapy in early breast cancer. Histopathology. 2018 Oct;73(4):545-558. doi: 10.1111/his.13523. Epub 2018 May 28. (2017 IF = 3.267)
    • Fielder GC, Yang TW, Razdan M, Li Y, Lu J, Perry JK, Lobie PE, Liu DX. The GDNF family: a role in cancer? Neoplasia. 2018 Jan;20(1):99-117. doi: 10.1016/j.neo.2017.10.010. Epub 2017 Dec 12. (2017 IF = 4.994)
    • Wang JJ, Chong QY, Sun XB, You ML, Pandey V, Chen YJ, Zhuang QS, Liu DX, Ma L, Wu ZS, Zhu T, Lobie PE. Autocrine hGH stimulates oncogenicity, epithelial-mesenchymal transition and cancer stem cell-like behavior in human colorectal carcinoma. Oncotarget. 2017 Oct 10;8(61):103900-103918. doi: 10.18632/oncotarget.21812. eCollection 2017 Nov 28. (2016 IF = 5.168)
    • Pandey V, Zhang M, Chong QY, You M, Raquib AR, Pandey AK, Liu DX, Liu L, Ma L, Jha S, Wu ZS, Zhu T, Lobie PE. Hypomethylation associated enhanced transcription of trefoil factor-3 mediates tamoxifen-stimulated oncogenicity of ER+ endometrial carcinoma cells. Oncotarget. 2017 Aug 24;8(44):77268-77291. doi: 10.18632/oncotarget.20461. eCollection 2017 Sep 29. (2016 IF = 5.168)
    • Chen JY, He XX, Ma C, Wu XM, Wan XL, Xing ZK, Pei QQ, Dong XP, Liu DX, Xiong WC, Zhu XJ. Netrin-1 promotes glioma growth by activating NF-κB via UNC5A. Sci Rep. 2017 Jul 14;7(1):5454. doi: 10.1038/s41598-017-05707-0. (2017 IF = 4.122)
    • Chen YJ, You ML, Chong QY, Pandey V, Zhuang QS, Liu DX, Ma L, Zhu T, Lobie PE. Autocrine Human Growth Hormone Promotes Invasive and Cancer Stem Cell-Like Behavior of Hepatocellular Carcinoma Cells by STAT3 Dependent Inhibition of CLAUDIN-1 Expression. Int J Mol Sci. 2017 Jun 15;18(6). pii: E1274. doi: 10.3390/ijms18061274. (2017 IF = 3.687)
    • Bugde P, Biswas R, Merien F, Lu J, Liu DX, Chen M, Zhou S, Li Y. The therapeutic potential of targeting ABC transporters to combat multi-drug resistance. Expert Opin Ther Targets. 2017 May;21(5):511-530. doi: 10.1080/14728222.2017.1310841. Epub 2017 Apr 3. (2017 IF = 4.598)
    • Dong-Xu Liu. Is SHON expression in tumours an accurate predictor of response to endocrine therapy in breast cancer? Oncology News. 2017 March/April, Volume 12, Issue 1, pp16-18. Web: https://www.oncologynews.biz (invited article)
    • Liu Z, Shi A, Song D, Han B, Zhang Z, Ma L, Liu D, Fan Z. Resistin confers resistance to doxorubicin-induced apoptosis in human breast cancer cells through autophagy induction. Am J Cancer Res 2017 Mar 1;7(3):574-583. eCollection 2017. (2017 IF = 3.998)
    • Geng P, Zhang Y, Liu X, Zhang N, Liu Y, Liu X, Lin C, Yan X, Li Z, Wang G, Li Y, Tan J, Liu DX, Huang B, Lu J. Automethylation of protein arginine methyltransferase 7 and its impact on breast cancer progression. FASEB J. 2017 Jun;31(6):2287-2300. doi: 10.1096/fj.201601196R. Epub 2017 Feb 10. (2017 IF = 5.595)
    • Li Z, Hou P, Fan D, Dong M, Ma M, Li H, Yao R, Li Y, Wang G, Geng P, Mihretab A, Liu D, Zhang Y, Huang B, Lu J. The degradation of EZH2 mediated by lncRNA ANCR attenuated the invasion and metastasis of breast cancer. Cell Death Differ. 2017 Jan;24(1):59-71. doi: 10.1038/cdd.2016.95. Epub 2016 Oct 7. (2017 IF = 8.000)
    • Feng J, Li L, Zhang N, Liu J, Zhang L, Gao H, Wang G, Li Y, Zhang Y, Li X, Liu D, Lu J, Huang B. Androgen and AR contribute to breast cancer development and metastasis: an insight of mechanisms. Oncogene. 2017 May 18;36(20):2775-2790. doi: 10.1038/onc.2016.432. Epub 2016 Nov 28. (2017 IF = 6.854)
    • Vouyovitch C, Perry JK, Liu DX, Bezin L, Vilain E, Diaz JJ, Lobie PE, Mertani HC. WNT4 mediates the autocrine effects of growth hormone in mammary carcinoma cells. Endocr-Relat Cancer. 2016 Jul;23(7):571-85. doi: 10.1530/ERC-15-0528. Epub 2016 Jun 20. (2017 IF = 5.331)
    • Abdel-Fatah TM, Agarwal D, Liu DX, Russell R, Rueda OM, Liu K, Xu B, Moseley PM, Green AR, Pockley AG, Rees RC, Caldas C, Ellis IO, Ball GR, Chan SY. SPAG5 as a prognostic biomarker and chemotherapy sensitivity predictor in breast cancer: a retrospective, integrated genomic, transcriptomic, and protein analysis. Lancet Oncology 2016 Jul;17(7):1004-18. doi: 10.1016/S1470-2045(16)00174-1. Epub 2016 Jun 14. (2017 IF = 36.418)
    • Evans A, Jamieson SM, Liu DX, Wilson WR, Perry JK. Growth hormone receptor antagonism suppresses tumour regrowth after radiotherapy in an endometrial cancer xenograft model. Cancer Lett. 2016 May 27;379(1):117-123. doi: 10.1016/j.canlet.2016.05.031. [Epub ahead of print] (2017 IF = 6.491)
    • Zhu S, Zhao L, Li Y, Hou P, Yao R, Tan J, Liu D, Han L, Huang B, Lu J, Zhang Y. Suppression of RAD21 induces senescence of MDA-MB-231 human breast cancer cells through RB1 pathway activation via c-Myc downregulation. J Cell Biochem. 2016 Jun;117(6):1359-69. doi: 10.1002/jcb.25426. Epub 2015 Nov 20. (2017 IF = 2.959)
    • Zhao L, Zhang Y, Gao Y, Geng P, Lu Y, Liu X, Yao R, Hou P, Liu D, Lu J, Huang B. JMJD3 promotes SAHF formation in senescent WI38 cells by triggering an interplay between demethylation and phosphorylation of RB protein. Cell Death Differ. 2015 Oct;22(10):1630-40. doi: 10.1038/cdd.2015.6. Epub 2015 Feb 20. (2017 IF = 8.000)
    • Perera O, Evans A, Pertziger M, MacDonald C, Chen H, Liu DX, Lobie PE, Perry JK. Trefoil factor 3 (TFF3) enhances the oncogenic characteristics of prostate carcinoma cells and reduces sensitivity to ionising radiation. Cancer Lett. 2015 May 28;361(1):104-11. doi: 10.1016/j.canlet.2015.02.051. Epub 2015 Mar 3. (2017 IF = 6.491)
    • Jiang Y, Marshall RJ, Walpole SC, Prieto-Merino D, Liu DX, Perry JK. An international ecological study of adult height in relation to cancer incidence for 24 anatomical sites. Cancer Causes & Control. 2015 Mar;26(3):493-9. doi: 10.1007/s10552-014-0520-1. Epub 2015 Jan 10. (2017 IF = 2.728)
    • Li L*, Liu DX*, Zhang N, Liang Q, Feng J, Yao M, Liu J, Li X, Zhang Y, Lu J, Huang B. SHON, a novel secreted protein, regulates epithelial-mesenchymal transition through transforming growth factor (TGF)-β signaling in human breast cancer cells. Int J Cancer. 2015 Mar 15;136(6):1285-95. doi: 10.1002/ijc.29110. Epub 2014 Aug 11. * Joint first author. (2017 IF = 7.360)
    • Guan J, MacGibbon A, Zhang R, Elliffe D, Moon S and Liu DX. Supplementation of complex milk lipid concentrate (CMLc) improved the memory of aged rats. Nutr Neurosci. 2015 Jan;18(1):22-9. doi: 10.1179/1476830513Y.0000000096. Epub 2013 Nov 20. (2016 IF = 3.313)
    • Yao R, Jiang H, Ma Y, Wang L, Wang L, Du J, Hou P, Gao Y, Zhao L, Wang G, Zhang Y, Liu DX, Huang B, Lu J. PRMT7 induces epithelial-to-mesenchymal transition and promotes metastasis in breast cancer, Cancer Res. 2014 Oct 1;74(19):5656-67. doi: 10.1158/0008-5472.CAN-14-0800. Epub 2014 Aug 18. (2017 IF = 9.130)
    • Guan J, Gluckman P, Yang P, Krissansen G, Sun X, Zhou Y, Wen J, Phillips G, Shorten PR, McMahon CD, Wake GC, Chan WH, Thomas MF, Ren A, Moon S, Liu DX. Cyclic glycine-proline regulates IGF-1 homeostasis by altering the binding of IGFBP-3 to IGF-1. Sci Rep. 2014 Mar 17;4:4388. doi: 10.1038/srep04388. (2017 IF = 4.122)
    • Jung Y, Abdel-Fatah TMA, Chan SYT, Nolan CC, Green AR, Ellis IO, Li L, Huang B, Lu J, Xu B, Chen L, Ma RZ, Zhang M, Wang J, Zhu T, Perry JK, Lobie PE, and Liu DX. SHON is a novel estrogen regulated oncogene in mammary carcinoma that predicts patient response to endocrine therapy. Cancer Res. 2013 Dec 1;73(23):6951-62. doi: 10.1158/0008-5472.CAN-13-0982. (2017 IF = 9.130)
    • Liang Q, Li L, Zhang J, Lei Y, Wang L, Liu DX, Feng J, Hou P, Yao R, Zhang Y, Huang B, Lu J. CDK5 is essential for TGF-β1-induced epithelial-mesenchymal transition and breast cancer progression. Sci Rep. 2013 Oct 14;3:2932. doi: 10.1038/srep02932. (2017 IF = 4.122)
    • Perry JK, Liu DX, Wu ZS, Zhu T, Lobie PE. Growth hormone and cancer: an update on progress. Current Opinion in Endocrinology, Diabetes and Obesity. 2013 Aug;20(4):307-13. doi: 10.1097/MED.0b013e328363183a. (2017 IF = 3.279)
    • Banerjee A, Wu ZS, Qian PX, Kang J, Liu DX, Zhu T, Lobie PE. ARTEMIN promotes de novo angiogenesis in ER negative mammary carcinoma through activation of TWIST1-VEGF-A signalling. PLoS One. 2012;7(11):e50098. doi: 10.1371/journal.pone.0050098. Epub 2012 Nov 21. (2017 IF = 2.766)
    • Banerjee A, Qian P, Wu ZS, Ren X, Steiner M, Bougen NM, Liu S, Liu DX, Zhu T, Lobie PE. Artemin Stimulates Radio- and Chemo-resistance by Promoting TWIST1-BCL-2-dependent Cancer Stem Cell-like Behavior in Mammary Carcinoma Cells. J Biol Chem. 2012 Dec 14;287(51):42502-15. doi: 10.1074/jbc.M112.365163. Epub 2012 Oct 24. (2017 IF = 4.010)
    • Hou L, Xu B, Mohankumar KM, Goffin V, Perry JK, Lobie PE, Liu DX. The prolactin receptor mediates HOXA1-stimulated oncogenicity in mammary carcinoma cells. Int J Oncol. 2012 Dec;41(6):2285-95. doi: 10.3892/ijo.2012.1660. Epub 2012 Oct 15. (2017 IF = 3.333)
    • Zhang J, Liang Q, Lei Y, Yao M, Li L, Gao X, Feng J, Zhang Y, Gao H, Liu DX, Lu J, Huang B. SOX4 induces epithelial-mesenchymal transition and contributes to breast cancer progression. Cancer Res. 2012 Sep 1;72(17):4597-608. doi: 10.1158/0008-5472.CAN-12-1045. Epub 2012 Jul 11. (2017 IF = 9.130)
    • Banerjee A, Wu ZS, Qian P, Kang J, Pandey V, Liu DX, Zhu T, Lobie PE. ARTEMIN synergizes with TWIST1 to promote metastasis and poor survival outcome in patients with ER negative mammary carcinoma. Breast Cancer Res. 2011;13(6):R112. doi: 10.1186/bcr3054. Epub 2011 Nov 7. (2017 IF = 6.142)
    • Kannan N, Kang J, Kong X, Tang J, Perry JK, Mohankumar KM, Miller LD, Liu ET, Mertani HC, Zhu T, Grandison PM, Liu DX, Lobie PE. Trefoil factor-3 is oncogenic and mediates anti-estrogen resistance in human mammary carcinoma. Neoplasia 2010 Dec;12(12):1041-53. (2017 IF = 4.994)
    • Pandey V, Jung Y, Kang J, Steiner M, Qian PX, Banerjee A, Mitchell MD, Wu ZS, Zhu T, Liu DX, Lobie PE. Artemin reduces sensitivity to doxorubicin and paclitaxel in endometrial carcinoma cells through specific regulation of CD24. Transl Oncol. 2010 Aug 1;3(4):218-29. (2017 IF = 3.071)
    • Tang JZ, Kong XJ, Banerjee A, Muniraj N, Pandey V, Steiner M, Perry JK, Zhu T, Liu DX, Lobie PE. STAT3α is oncogenic for endometrial carcinoma cells and mediates the oncogenic effects of autocrine human growth hormone. Endocrinology. 2010 Sep;151(9):4133-45. doi: 10.1210/en.2010-0273. Epub 2010 Jul 28. (2017 IF = 3.961)
    • Tang JZ, Kong X, Kang J, Fielder GC, Steiner M, Perry JK, Wu ZS, Yin Z, Zhu T, Liu DX, Lobie PE. Artemin stimulated progression of human non-small cell lung carcinoma is mediated by BCL2. Mol Cancer Ther. 2010 Jun;9(6):1697-708. doi: 10.1158/1535-7163.MCT-09-1077. Epub 2010 Jun 8. (2017 IF = 5.365)
    • Kang J, Qian PX, Fielder G, Perry JK, Zhu T, Liu DX, Lobie PE. Artemin is estrogen regulated and mediates anti-estrogen resistance in mammary carcinoma cells. Oncogene. 2010 Jun 3;29(22):3228-40. doi: 10.1038/onc.2010.71. Epub 2010 Mar 22. (2017 IF = 6.854)
    • Vidal LJ, Perry JK, Vouyovitch CM, Pandey V, Brunet-Dunand SE, Mertani HC, Liu DX, Lobie PE. PAX5α enhances the epithelial behaviour of human mammary carcinoma cells. Mol Cancer Res. 2010 Mar;8(3):444-56. doi: 10.1158/1541-7786.MCR-09-0368. Epub 2010 Mar 2. (2017 IF = 4.597)
    • Pandey V, Qian PX, Kang J, Perry JK, Mitchell MD, Yin Z, Wu ZS, Liu DX, Zhu T, and Lobie PE. Artemin stimulates oncogenicity and invasiveness of human endometrial carcinoma cells. Endocrinology. 2010 Mar;151(3):909-20. doi: 10.1210/en.2009-0979. Epub 2010 Jan 29. (2017 IF = 3.961)
    • Tang JZ, Zuo ZH, Kong XJ, Steiner M, Yin Z, Perry JK, Zhu T, Liu DX, Lobie PE.  Signal transducer and activator of transcription (STAT)-5A and STAT5B differentially regulate human mammary carcinoma cell behavior. Endocrinology. 2010 Jan;151(1):43-55. doi: 10.1210/en.2009-0651. Epub 2009 Dec 4. (2017 IF = 3.961)
    • Amiry N, Kong X, Muniraj N, Kannan N, Grandison PM, Lin J, Yang Y, Vouyovitch CM, Borges S, Perry JK, Mertani HC, Zhu T, Liu D, Lobie PE. Trefoil factor-1 (TFF1) enhances oncogenicity of mammary carcinoma cells. Endocrinology. 2009 Oct;150(10):4473-83. doi: 10.1210/en.2009-0066. Epub 2009 Jul 9. (2017 IF = 3.961)
    • Kang J, Perry JK, Pandey V, Fielder GC, Mei B, Qian PX, Wu ZS, Zhu T, Liu DX, Lobie PE. Artemin is oncogenic for human mammary carcinoma cells. Oncogene. 2009 May 14;28(19):2034-45. Epub 2009 Apr 13. (2017 IF = 6.854)
    • Liu DX, Lobie PE. Transcriptional activation of p53 by Pitx1. Cell Death Differ. 2007 Nov;14(11):1893-907. Epub 2007 Aug 31. (2017 IF = 8.000)

     

    Patents:

    • Liu DX, Lobie PE. Polypeptides and Polynucleotides for Artemin and Related Ligands, and Methods of Use Thereof. The State Intellectual Property Office of the People's Republic of China: Application No. CN 200880104674 filed on 25/06/2008; published (Application number CN 200880104674.9) on 25/06/2008; Granted: on 24/05/2017. (URL: https://www.google.com/patents/CN101932602A)
    • Liu DX, Abdel−Fatah TMA, Perry JK, Lu J, Huang B, Chan SYT, Green AR, Ellis IO. “SHON as a prognostic biomarker for cancer and as a predictor of response to endocrine therapy”. National Phase Application (National Number US15/103581) was filed with the United States Patent and Trademark Office on 10/06/2016.
    • Liu DX, Abdel−Fatah TMA, Perry JK, Lu J, Huang B, Chan SYT, Green AR, Ellis IO. “SHON as a prognostic biomarker for cancer and as a predictor of response to endocrine therapy”. National Phase Application (National Number CN201380063947.0) was filed with the State Intellectual Property Office of the People's Republic of China on 26/04/2016, and published on 10/08/2016. (URL: https://www.google.co.nz/patents/CN105849565A?cl=en&dq=CN201380063947)
    • Liu DX, Abdel−Fatah TMA, Perry JK, Lu J, Huang B, Chan SYT, Green AR, Ellis IO. “SHON as a prognostic biomarker for cancer and as a predictor of response to endocrine therapy”. National Phase Application (National Number EP2013846652) was filed with European Patent Office on 14/05/2015. Published on 21/10/2015. (URL: https://www.google.co.nz/patents/EP2932272A1?dq=2013846652&cl=en)
    • Liu DX, Abdel−Fatah TMA, Perry JK, Lu J, Huang B, Chan SYT, Green AR, Ellis IO. “SHON as a prognostic biomarker for cancer and as a predictor of response to endocrine therapy”. National Phase Application (National Number AU2013332512) was filed with the IP Australia on 14/05/2015. Published on 04/06/2015 and amended on 09/06/2016. (URL: http://www.ipaustralia.com.au/applicant/ma-runlin-z/patents/AU2013332512/)
    • Liu DX, Lobie PE. Polypeptides and Polynucleotides for Artemin and Related Ligands, and Methods of Use Thereof. European Patent Office (EPO) Application No. EP20080779128 filed on 26/06/2008; published (EPO Patent No. EP2164870 B1) on 09/12/2015; Granted: on 09/12/2015. (URL: http://www.google.com/patents/EP2164870B1)
    • Liu DX, Lobie PE. “Polypeptides and polynucleotides for artemin and related ligands and methods of use thereof”. United States continuation patent application 14/491198 filed on 19/09/2014. Published (Publication number US20150030605 A1) on Jan 29, 2015. (URL: http://www.google.com/patents/US20150030605)
    • Liu DX, Abdel−Fatah TMA, Perry JK, Lu J, Huang B, Chan SYT, Green AR, Ellis IO. “SHON as a prognostic biomarker for cancer and as a predictor of response to endocrine therapy”. PCT International Patent Application (PCT/NZ/2013/000188) filed on 17/10/2013. Published on 24/04/2014. (URL: http://patentscope.wipo.int/search/en/WO2014062069)
    • Liu DX, Abdel−Fatah TMA, Perry JK, Lu J, Huang B, Chan SYT, Green AR, Ellis IO. “SHON as a prognostic biomarker for cancer and as a predictor of response to endocrine therapy”. Provisional specification (NZ603056) filed on 17/10/2012. Full application (NZ616981) filed on 23/10/2013, accepted on 23 Apr 2015, and published on 24 Apr 2015. Granted: on July 28, 2015. (URL: https://www.iponz.govt.nz/manage-ip. Click “Search patents” for case number “616981”)
    • Liu DX, Abdel−Fatah TMA, Perry JK, Lu J, Huang B, Chan SYT, Green AR, Ellis IO. “SHON as a prognostic marker and predictor of response to endocrine therapy”. Provisional specification (NZ603056) filed on 17/10/2012.
    • Jun Lu, Dong-Xu Liu, Jian Guan, Margaret Anne Brimble, Paul William Richard Harris, Baiqu Huang. “Application of cGP and derivatives in preparation of medicine for inhibiting tumor growth and regeneration”. Application (CN201210392352.7) filed in Oct 16, 2012 and published (CN103100080 A) on May 15, 2013. Granted: on Jun 18, 2014. (URL: http://www.google.com/patents/CN103100080A?cl=en; https://www.google.com/patents/CN103100080B?cl=fr)
    • Lobie PE, Liu DX. “Artemin antibodies and use thereof”. US Provisional Patent Application 61/234902. Filed 19/08/2009.
    • Liu DX, Lobie PE “Polypeptides and polynucleotides for artemin and related ligands and methods of use thereof”. National Phase Application (National Number US_45229108_A) was filed with the United States Patent and Trademark Office on 25/06/2008 and published (US 2011/0206673 A1) on 25/08/2011. (URL: https://www.lens.org/lens/patent/US_2011_0206673_A1)
    • Liu DX, Lobie PE “Polypeptides and polynucleotides for artemin and related ligands and methods of use thereof” filed as provisional specification in the USA as US 60/946394 on 27/06/2007, and PCT/NZ2008/000152 filed 25/06/2008 and published on 31/12/2008. (URL: http://www.wipo.int/patentscope/search/en/WO2009002193)
    • Liu DX, Lobie PE. “Novel saratan polypeptides and polynucleotides and methods of use thereof” filed as provisional specification in the USA as US 60/908967 on 29/03/2007, became PCT/NZ2008/000069 filed 31/03/2008. (URL: http://www.wipo.int/patentscope/search/en/WO2008121007)
    • Liu DX, Lobie PE. Inhibition of SF20 to treat metastatic disorders. Provisional Australian Application filed 29/10/2006.

    Awards:

    Merck KGaA Grant for Oncology Innovation (GOI) Award (2016)   
    Genesis Oncology Trust Professional Development Award (2014)
    Auckland Cancer Society - Travel Award (2013)
    International Central Network Fund, University of Auckland (2013)
    Auckland Medical Research Foundation - Travel Award (2013)
    Research Scholarship by National University of Singapore (1997-2000)
    Overseas Research Student Award by the British Government (1995-1997)
    Graduate Scholarship by University College London (1995) (not taken)
    Excellent Thesis Prize by the Chinese Academy of Sciences (1992)
    People’s Scholarship by the Chinese Academy of Sciences (1989-1992)
    People’s Scholarship by the China Agricultural University, Beijing (1983-1987)